Scopus
YÖKSİS DOI Eşleşti
SJR Q2
Comparison of Maternal and Fetal Plasma X Box Binding Protein 1 Levels Between Pregnancies With Fetal Growth Retardation and Healthy Controls
American Journal of Reproductive Immunology · Mayıs 2025
YÖKSİS Kayıtları
Comparison of Maternal and Fetal Plasma X Box Binding Protein 1 Levels Between Pregnancies With Fetal Growth Retardation and Healthy Controls
American Journal of Reproductive Immunology · 2025 SCI-Expanded
Prof. Dr. ÇETİN ÇELİK →
YÖKSİS Kayıtları — ISSN Eşleşmesi
A Prospective Case-Control Study Analyzes 12 Thrombophilic Gene Mutations in Turkish Couples with Recurrent Pregnancy Loss
2010 ISSN: 10467408 SCI-Expanded
Doç. Dr. NADİR KOÇAK →
Can altered colostrum miRNA expression profile after cesarean delivery be a risk factor for autoimmune diseases?
2021 ISSN: 1046-7408 SCI-Expanded Q2
Prof. Dr. FATMA HÜMEYRA YERLİKAYA AYDEMİR →
Comparison of Maternal and Fetal Plasma X Box Binding Protein 1 Levels Between Pregnancies With Fetal Growth Retardation and Healthy Controls
2025 ISSN: 1046-7408 SCI-Expanded Q3
Prof. Dr. ÇETİN ÇELİK →
Makale Bilgileri
ISSN10467408
Yayın TarihiMayıs 2025
Cilt / Sayfa93
Scopus ID2-s2.0-105004686569
Özet
Objective: This study aimed to compare maternal and cord serum X box binding protein 1 (XBP-1) levels in pregnant women with fetal growth restriction (FGR) with healthy pregnancies. Materials and Methods: This prospective case-control study was conducted between January 1, 2022, and May 31, 2022, at the Gynecology and Obstetrics Clinic of Selçuk University Faculty of Medicine Hospital. Forty-three pregnant women and fetuses with isolated FGR with abdominal circumference (AC) or estimated fetal weight (EFW) below the 10th percentile according to ultrasonographic measurements constituted the study group; 43 healthy pregnant women and fetuses constituted the control group. Serum XBP-1 levels in prenatal maternal and cord blood were measured by ELISA and compared between the two groups. Results: The mean maternal blood XBP-1 level was 1910.22 ± 607.07 ng/L in the FGR group and 1638.89 ± 385.80 ng/L in the control group (p = 0.044). Cord blood XBP-1 levels were 1837.72 ± 942.67 and 1346.14 ± 664.09 ng/L in the study and control groups, respectively (p = 0.006). Maternal XBP-1 levels were found to discriminate FGR with a sensitivity of 80% and specificity of 60% at a value of 1405 ng/L. For cord blood XBP-1, 869.2 ng/L was the best cut-off, with 98% sensitivity and 67% specificity. In ROC analysis, the area under the curve was found to be 0.626 and 0.671, and p values were found to be 0.044 and 0.006 for maternal serum XBP-1 and cord blood XBP-1, respectively. Conclusions: In the study, serum XBP-1 levels in both maternal and fetal umbilical cord blood were found to be higher in patients with FGR. Considering the role of XBP-1 in metabolic pathways and cellular functions, XBP-1 may have an important role in the pathophysiology of FGR.
Yazarlar (5)
1
Sena Ünlü
ORCID: 0000-0002-8373-7213
2
Nizamettin Bozbay
ORCID: 0000-0001-9632-5093
3
Fikret Akyürek
4
Gökçen Örgül
ORCID: 0000-0003-0578-4230
5
Çetin Çelik
ORCID: 0000-0001-6165-5092
Anahtar Kelimeler
fetal growth restriction
pregnancy
X box binding protein 1
Kurumlar
Selçuk Tip Fakültesi
Konya Turkey
Scimago Dergi (ISSN Eşleşmesi)
American Journal of Reproductive Immunology
Q2
SJR Skoru0,722
H-Index123
YayıncıWiley-Blackwell Publishing Ltd
ÜlkeUnited Kingdom
Obstetrics and Gynecology (Q2)
Reproductive Medicine (Q2)
Immunology (Q3)
Immunology and Allergy (Q3)